CTLA4 and melanoma: Besides immunotherapy with CTLA4 and PD1 inhibitors, we have recently reported the efficacy of targeting the inducible T-cell co-stimulator (ICOS)/ICOS ligand (ICOS-L) dyad in mouse models of melanoma [4].